Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct:39:22-29.
doi: 10.1016/j.smim.2018.10.004. Epub 2018 Oct 23.

Correlates of GLA family adjuvants' activities

Steven G Reed  1 , Darrick Carter  2 , Corey Casper  3 , Malcolm S Duthie  4 , Christopher B Fox  5
Affiliations
Review

Correlates of GLA family adjuvants' activities

Steven G Reed et al. Semin Immunol. 2018 Oct.

Abstract

Lipopolysaccharide (LPS) is a well-defined agonist of Toll-like receptor (TLR) 4 that activates innate immune responses and influences the development of the adaptive response during infection with Gram-negative bacteria. Many years ago, Dr. Edgar Ribi separated the adjuvant activity of LPS from its toxic effects, an effort that led to the development of monophosphoryl lipid A (MPL). MPL, derived from Salmonella minnesota R595, has progressed through clinical development and is now used in various product-enabling formulations to support the generation of antigen-specific responses in several commercial and preclinical vaccines. We have generated several synthetic lipid A molecules, foremost glucopyranosyl lipid adjuvant (GLA) and second-generation lipid adjuvant (SLA), and have advanced these to clinical trial for various indications. In this review we summarize the potential and current positioning of TLR4-based adjuvant formulations in approved and emerging vaccines.

Keywords: Adjuvant; Formulation; Monophosphoryl lipid A; Toll-like receptor 4; Vaccine.

PubMed Disclaimer

References

    1. Takayama K, Ribi E, Cantrell JL, Isolation of a nontoxic lipid a fraction containing tumor regression activity, Cancer Res. 41 (1981) 2654–2657. - PubMed
    1. Ribi E, Purification and Structural Determination of Nontoxic LipidA Obtained from the Lipopolysaccharide of Salmonella Typhimurium, October. 257 (1982) 11808–11815. - PubMed
    1. Ribi E, Beneficial modification of the endotoxin molecule, J. Biol. Response Mod 3 (1984) 1–9. - PubMed
    1. Stoute J, Slaoui M, Heppner D, Momin P, Kester K, Desmons P, Wellde B, Garçon N, Krzych U, Marchand M, A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria., … Engl. J …. (1997). http://www.nejm.org/doi/full/10.1056/NEJM199701093360202. - DOI - PubMed
    1. Kester KE, Cummings JF, Ofori‐Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois M, Lievens M, Cohen J, Ballou WR, Heppner DG Jr., Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection, J. Infect. Dis 200 (2009) 337–346. doi:10.1086/600120. - DOI - PubMed

Publication types

MeSH terms